Proxy Materials

Kalaris Therapeutics, Inc. Filed 2024-04-23 Acc 0001193125-24-106981

Documents 1

2025-07-01 DEFA14A Proxy Materials
2024-04-23 DEFA14A Proxy Materials
2024-04-23 4 Chief Executive Officer sold 9,601 shares at $0.75 ($7,207)
2024-04-23 4 General Counsel sold 1,383 shares at an average $0.75 ($1,038)
2024-04-23 4 Chief Accounting Officer sold 953 shares at an average $0.75 ($715)
2024-04-23 4 See Remarks sold 3,378 shares at an average $0.75 ($2,534)
2023-03-31 DEFA14A Proxy Materials

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

Loading d621337ddefa14a.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…